Cantor Fitzgerald Thinks Collegium Pharmaceutical’s Stock is Going to Recover


In a report released today, Brandon Folkes from Cantor Fitzgerald maintained a Buy rating on Collegium Pharmaceutical (COLL), with a price target of $35. The company’s shares opened today at $15.18, close to its 52-week low of $13.10.

Folkes wrote:

“We expect upwards earnings revisions to levels not reflected in FactSet consensus to drive COLL shares higher. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $35 price target. The Disclosure Section may be found on pages 5 – 6.Valuation We use a blend of DCF and EV/EBITDA to arrive at our $35 price target.”

According to TipRanks.com, Folkes is a 3-star analyst with an average return of 2.9% and a 46.8% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Eagle Pharmaceuticals Inc, and ANI Pharmaceuticals Inc.

Collegium Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $33.33.

See today’s analyst top recommended stocks >>

Based on Collegium Pharmaceutical’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $16.5 million. In comparison, last year the company had a GAAP net loss of $17.4 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta® ER and Nucynta.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts